Sesen Bio, Inc.
245 First Street, Suite 1800
Cambridge, MA 02142
June 6, 2018
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: | Sesen Bio, Inc. |
Registration Statement on Form S-3
Filed March 19, 2018
File No. 333-223750
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Sesen Bio, Inc. (the “Company”), formerly Eleven Biotherapeutics, Inc., hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended to date, and declare such Registration Statement effective as of 4:00 p.m., Eastern Daylight Time, on June 8, 2018, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours, |
Sesen Bio, Inc. |
/s/ Stephen A. Hurly | ||
By: | Stephen A. Hurly | |
Title: | President and Chief Executive Officer | |